Navigation Links
Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
Date:12/7/2011

LONDON, December 7, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi) therapeutics company, announces a positive outcome from the oral hearing on 6 December 2011 at the European Patent Office (EPO) over opposition to Silence's granted European Patent EP 1 536 827 "Further use of protein kinase N beta".

The granted patent refers to the gene target PKN3, protein kinase N beta, targeted by Silence's lead program Atu027, which is currently in a Phase I clinical study. The Opposition division of the EPO decided to uphold the patent in amended form.

Claim one of the patent relates to the use of protein kinase N beta as a downstream target of the PI3 kinase pathway. Claim two relates to the use of protein kinase N beta as a downstream drug target of the PI3 kinase pathway in a screening process. Both of these claims are maintained as granted, and also the use claims where manufacture of a diagnostic agent is based on use of protein kinase N beta as such (or use of antibodies, spiegelmers, aptamers, ribozymes, antisense molecules and siRNA molecules directed against protein kinase N beta and the nucleic acid molecule coding for these, respectively).

In connection with the use claims where protein kinase N beta as such (or antibodies, spiegelmers, aptamers, ribozymes, antisense molecules and siRNA molecules directed against protein kinase N beta and the nucleic acid molecule coding therefore, respectively) are used for the manufacture of a medicament, the diseases for which such medicament is to be used are now restricted to metastatic cancers. This is the focus of Silence's currently ongoing Atu027 Phase I study with late-stage cancer patients.

Commenting on today's announcement, Thomas Christély, Chief Exe
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Provides Corporate and Development Update
2. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
3. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
4. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
5. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
8. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
9. Silence Therapeutics Appoints New Vice President of Research
10. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
11. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Local veterinarian, Dr. ... Hospital are seeking candidates to participate in an investigational ... The ultimate goal of this study is to ... into one or two arthritically affected joints can help ... , Candidates for the current investigational study must be ...
(Date:8/29/2014)... Due to a misstatement posted by the Family Resource ... Center, LLC ( ASCTC ) was reported as an entity ... benefit ALS patients. Because of ASCTC's exclusive focus on ... therapeutic applications, FRC listed ASCTC as one of several alternatives ... not to support research that requires the death of human ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... Nevada City, CA (PRWEB) August 28, 2014 ... and sanitation products for the food processing industry, is ... conducting a side-by side comparison of the E2 soap ... Q E2 Sanitizing Foam Soap . Hand hygiene ... pathogens in the food processing environment. Six key criteria ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... ATLANTA, May 1 CryoLife, Inc., (NYSE: ... company, announced today,that Harvey Morgan has been elected ... Morgan is a Managing Director at Bentley,Associates L.P., ... more than 35 years of investment banking experience ...
... accelerating market penetration and revenue growth, SCOTTSDALE, ... technology company that markets the Provant(R) Wound Therapy,System, ... as Vice,President of Marketing. Most recently Mr. Robey ... Inc (KCI) for the V.A.C.(R) Therapy,brand, during the ...
... SEATTLE, May 1 Therapies under development to ... growth factor,(IGF-1) to activate its target receptor could ... gene -- p53 -- is already,compromised, according to ... Center., IGF-1 is a polypeptide hormone that ...
Cached Biology Technology:Harvey Morgan Joins CryoLife Board of Directors 2Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing 2New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor 2New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor 3
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
(Date:8/29/2014)... in German . ... natural nitrogen cycle on Earth and in biological wastewater ... to depend on nitrite as their source of energy. ... a microbiologist at the University of Vienna, has now ... alternative source of energy. The oxidation of hydrogen with ...
(Date:8/29/2014)... Bend them, stretch them, twist them, fold them: modern ... extraordinary technological potential, whether as artificial skin or electronic ... use remains a challenge but a new way of ... could be a game-changer. , Previous success in ... on the use of precious gold and silver nanowires. ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Copper shines as flexible conductor 2
... to treat bacterial infections causes a continual and vicious ... and spread of resistant strains, forcing the use of ... what if it doesn,t have to be that way? ... Biochemistry and Molecular Biology,s annual meeting, titled "Driving backwards ...
... We all know that eating a calcium-rich diet is ... concept is clearly on display in any elementary school ... with celebrity icons encouraging children to make sure they ... urging school-aged children to pay attention to their dairy ...
... genes out of action allows researchers to learn what genes ... Utah biologists pioneered the field. Mario Capecchi won a Nobel ... to cripple fruit fly genes. Now, biologist Erik Jorgensen and ... nematode worms. "We developed a method that allows us ...
Cached Biology News:Putting bacterial antibiotic resistance into reverse 2Study suggests a much earlier onset for bone problems 2Study suggests a much earlier onset for bone problems 3Worm genes KO'd 2Worm genes KO'd 3Worm genes KO'd 4Worm genes KO'd 5